COLL - Company ID 0001267565
The table below shows COLLEGIUM PHARMACEUTICAL, INC's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Revenue | $193.52M | $205.45M | $209.36M | $188.00M | $177.76M | $181.95M |
| Cost of revenue | $76.27M | $77.07M | $80.19M | $79.62M | $80.43M | $83.66M |
| Gross profit | $117.25M | $128.38M | $129.17M | $108.38M | $97.32M | $98.29M |
| R&D | - | - | - | - | - | - |
COLLEGIUM PHARMACEUTICAL, INC reported annual revenue of $780.57M for fiscal year 2025. That is up 23.6% from $631.45M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $1.71M (FY 2016) to $780.57M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $86.35M | $67.64M | $67.10M | $73.64M | $76.42M | $63.09M |
| Operating income | $30.90M | $60.76M | $62.09M | $35.10M | $21.69M | $38.11M |
| Income tax | $4.24M | $12.07M | $11.93M | $5.04M | $705.00K | $4.73M |
| Net income | $14.50M | $16.96M | $31.51M | $11.98M | $2.42M | $12.54M |
| EPS (diluted) | $0.40 | $0.46 | $0.84 | $0.34 | $0.07 | $0.36 |